• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
Ursodeoxycholic Acid

Ursodeoxycholic Acid

Product ID U6873
Cas No. 128-13-2
Purity ≥98%
Product Unit SizeCostQuantityStock
1 g $60.10 In stock
5 g $180.30 In stock
25 g $375.60 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Ursodeoxycholic acid is an endogenous secondary bile acid produced by bacterial metabolism of bile acids in the intestines. Ursodeoxycholic acid decreases cholesterol absorption, dissolves gallstones, and treats cirrhosis and other liver diseases. This compound exhibits immunosuppressive, antioxidative, hepatoprotective, anticancer, and gastrointestinal motility modulating activities. In animal models, ursodeoxycholic acid decreases spleenocyte proliferation and levels of IL-2, L-6, and IFN-γ, increases levels of IL-10, and prevents allograft rejection. In other animal models, this compound increases levels of glutathione and decreases levels of malondialdehyde, myeloperoxidase, and ROS. In colon cancer cells, ursodeoxycholic acid inhibits cellular proliferation and induces apoptosis; similarly, it also induces differentiation, senescence, and HDAC6-dependent hypoacetylation. In other cancer models, this compound inhibits telomerase and may exhibit chemopreventive potential. In vivo, ursodeoxycholic acid decreases gastrointestinal transit time and increases gastric emptying rates.

Product Info

Cas No.

128-13-2

Purity

≥98%

Formula

C24H40O4

Formula Wt.

392.57

Chemical Name

(3α,5β,7β)-3,7-Dihydroxycholan-24-oic acid

IUPAC Name

(4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2, 3,4,5,6,7,8,9,11,12,14,15,16, 17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid

Synonym

Ursodiol, Actigall, Delursan, Desol, Litursol, Peptarom, Urdes, Ursofalk, Ursolvan

Melting Point

203°C

Solubility

Insoluble in water. Soluble in ethanol. Slightly soluble in chloroform. Soluble in DMSO (>100 mg/mL).

Appearance

White Fine Crystalline Powder

Shipping and Storage

Store Temp

Ambient

Ship Temp

Ambient

Downloads

MSDS

U6873 MSDS PDF

Info Sheet

U6873 Info Sheet PDF

References

Zhang Q, Nakaki T, Iwami D, et al. Induction of regulatory T cells and indefinite survival of fully allogeneic cardiac grafts by ursodeoxycholic acid in mice. Transplantation. 2009 Dec 27;88(12):1360-70. PMID: 20029332.

El-Sherbiny GA, Taye A, Abdel-Raheem IT. Role of ursodeoxycholic acid in prevention of hepatotoxicity caused by amoxicillin-clavulanic acid in rats. Ann Hepatol. 2009 Apr-Jun;8(2):134-40. PMID: 19502657.

Akare S, Jean-Louis S, Chen W, et al. Ursodeoxycholic acid modulates histone acetylation and induces differentiation and senescence. Int J Cancer. 2006 Dec 15;119(12):2958-69. PMID: 17019713.

Colecchia A, Mazzella G, Sandri L, et al. Ursodeoxycholic acid improves gastrointestinal motility defects in gallstone patients. World J Gastroenterol. 2006 Sep 7;12(33):5336-43. PMID: 16981264.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • V9201

    VX-11e

    ERK2 inhibitor, potential AurKA, GSK3, CDK2, FL...

    ≥98%
  • O456505

    Olmutinib

    EGFR inhibitor.

    ≥98%
  • T7032

    Triamcinolone

    Synthetic steroid; glucocorticoid agonist.

    ≥98%
  • N1984

    Neuropeptide FF

    Endogenous RF-amide peptide, involved in nocice...

    ≥95%
  • M5877

    Motesanib Diphosphate

    VEGFR, PDGFR, c-Kit, RET inhibitor.

    ≥98%
  • V1668

    Vemurafenib

    B-Raf inhibitor.

    ≥98%
  • I0481

    Ibuprofen

    NSAID; COX-1/2 inhibitor.

    ≥98%
  • P200002

    PF-07321332

    Inhibitor of coronaviruses

    ≥99%
  • Z3463

    Ziprasidone

    5-HT1A agonist, D2, 5-HT1D antagonist.

    ≥98%
  • Y4800

    YM-155

    Survivin inhibitor.

    ≥99%
  • R3222

    Rifamycin SV Monosodium

    Ansamycin; bacterial DNA-dependent RNA polymera...

    ≥98%
  • A044178

    Abemaciclib mesylate

    CDK inhibitor.

    ≥98%
  • W0269

    (±)-Warfarin

    Coumarin; VKORC1 inhibitor.

    ≥98%
  • V014457

    Valnemulin Hydrochloride

    Pleuromutilin

    ≥98%
  • D5898

    Doxycycline Monohydrate

    Tetracycline; protein translation inhibitor, MM...

    ≥97%
  • D3448

    Dimethyl Fumarate

    Fumaric acid methyl ester; nAChR agonist, indir...

    ≥98%
  • G0245

    Gallocatechin Gallate

    Polyphenol found in Camilla sinensis; HIV integ...

    ≥98%
  • K5604

    Kobe 0065

    Ras inhibitor.

    ≥99%
  • C9677

    Cyclocytidine Hydrochloride

    Pyrimidine nucleoside analog; DNA synthesis inh...

    ≥98%
  • T3200

    Ticagrelor

    Nucleoside (adenosine) analog; P2Y12 antagonist...

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only